Selvita to Host Conference Call and Webcast on Thursday, March 28

Thursday, March 21, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

KRAKOW, Poland, March 21, 2019 /PRNewswire/ -- Selvita (WSE: SLV), a clinical stage company

engaged in the research and development of novel cancer therapies as well as provision of drug discovery and development services, today announced that it will report fourth quarter and year end 2018 financial results on Thursday,
March 28, 2019
, and provide a corporate update. Management will host a live video webcast at 10:00 a.m. CET/5:00 a.m. EST (Polish language).

The live webcast can be accessed live.selvita.com. An archived version of the webcast will be available following the call in the Investor Relations section of the Company's website at www.selvita.com.

Selvita will also host a press conference for investors and media in Warsaw, Poland.

About Selvita

Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.

Contact: Julia Balanova (investors)+1-646-378-2936jbalanova@troutgroup.com 

Rich Allan (media)+1-646-378-2958rallan@troutgroup.com 

Malgorzata Syjud (corporate)+48-660-797-362malgorzata.syjud@selvita.com

Cision View original content:http://www.prnewswire.com/news-releases/selvita-to-host-conference-call-and-webcast-on-thursday-march-28-300816329.html

SOURCE Selvita



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store